Physician profile
Ming-Wei Wu
NPI 1578500336
$36,970.69
in general payments reported to CMS, 2019-2025
23 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,088 · 2020: $409 · 2021: $636 · 2022: $33K · 2023: $820 · 2024: $476 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,487 · Consulting Fee: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,486.72 |
| Consulting Fee | $110.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Triad Life Sciences INC. | $32,000.00 | 2022 | |
| Kerecis Limited | $1,619.20 | 2020-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Kci USA, INC. | $975.95 | 2019-2023 | V.A.C. Veraflo, Activ.A.C. |
| Smith+Nephew, INC. | $807.38 | 2019-2025 | Collagenase Santyl |
| Melinta Therapeutics, LLC | $483.62 | 2019-2024 | Kimyrsa, Rezzayo |
| Organogenesis INC. | $205.82 | 2019-2025 | Puraply Wound Matrix |
| Paratek Pharmaceuticals, INC. | $140.85 | 2019-2025 | Nuzyra |
| Next Science LLC | $110.83 | 2024 | Xperience, Blastx, Surgx |
| Novo Nordisk INC | $107.59 | 2019-2023 | Rybelsus, Ozempic |
| Solventum Corporation | $102.21 | 2024-2025 | Activ.A.C., V.A.C. Veraflo |
| Ascensia Diabetes Care US INC. | $74.63 | 2025 | |
| Reddress USA, INC. | $70.02 | 2024 | |
| Amgen INC. | $45.14 | 2020-2025 | Krystexxa |
| Mannkind Corporation | $37.54 | 2021 | |
| Esperion Therapeutics, INC. | $34.00 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Misonix INC | $29.98 | 2020-2021 | |
| Hartmann USA, INC. | $24.44 | 2022 | |
| Abbvie INC. | $23.58 | 2024 | |
| Horizon Therapeutics Plc | $21.72 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.24 | 2022 | |
| Tactile Systems Technology INC | $14.57 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.28 | 2021 | |
| Reprise Biomedical, INC. | $9.10 | 2024 | Miro3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ming-Wei Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.